All patients | Propensity-matched patients | |||||
---|---|---|---|---|---|---|
Redo-TAVI (n = 52) | Redo-AVR (n = 167) | Redo-TAVI (n = 40) | Redo-AVR (n = 40) | |||
Variables | No. (%) | No. (%) | p value | No. (%) | No. (%) | p value |
Age (years) | 82 ± 5 | 72 ± 9 | 0.07 | 81 ± 4 | 80 ± 3 | >0.99 |
Log EuroSCORE|| | 25 ± 5 | 17 ± 2 | 0.11 | 24 ± 6 | 19 ± 6 | 0.58 |
STS risk score | 11 ± 4 | 9 ± 2 | 0.07 | 11.1 ± 2.8 | 10.4 ± 3 | 0.65 |
Male | 31 (60) | 92 (55) | 0.44 | 29 (73) | 29 (73) | >0.99 |
Arterial hypertension | 22 (42) | 106 (63) | 0.14 | 16 (40) | 18 (45) | 0.69 |
Pulmonary hypertension | 16 (31) | 72 (43) | 0.24 | 5 (13) | 5 (13) | >0.99 |
Diabetes | 20 (38) | 43 (26) | 0.42 | 17 (42) | 14 (35) | 0.54 |
CAD‡ | 45 (87) | 42 (25) | 0.03 | 33 (83) | 30 (75) | 0.46 |
COPD§ | 19 (36) | 37 (22) | 0.67 | 9 (23) | 8 (20) | 0.81 |
Chronic renal failure* | 30 (58) | 21 (12) | 0.05 | 20 (50) | 16 (40) | 0.43 |
Peripheral vascular disease | 23 (44) | 24 (14) | 0.04 | 13 (33) | 11 (27) | 0.43 |
Cerebrovascular disease | 20 (38) | 31 (18) | 0.07 | 9 (23) | 8 (20) | 0.81 |
LV-EF < 30¶ | 21 (40) | 39 (23) | 0.06 | 9 (23) | 9 (23) | >0.99 |
Mean ejection fraction | 39 ± 18 | 44 ± 14 | 0.62 | 48 ± 14 | 47 ± 12 | 0.77 |
Aortic valve area (cm) | 0.65 ± 0.24 | 0.5 ± 0.31 | 0.46 | 0.63 ± 0.29 | 0.68 ± 0.31 | 0.65 |
Mean pressure gradient (echo; mmHg) | 59 ± 18 | 57 ± 14 | 0.59 | 57 ± 21 | 51 ± 16 | 0.56 |
Peak to peak gradient (invasive; mmHg) | 67 ± 27 | 70 ± 35 | 0.55 | 69 ± 36 | 65 ± 34 | 0.58 |
Mean time interval between initialand current cardiac procedure (years) | 7 ± 4 | 11 ± 8 | 0.60 | 7 ± 5 | 8 ± 6 | 0.78 |